Dalia M.
295 posts
Dalia M.
@DCCancerDoc
Cancer Doctor in Washington, D.C. Sherlock loving Hematologist Oncologist. Data science and informatics lover. Reality 🧜♀️ 🎹 🎤⚽️
Washington DC Entrou em Ocak 2010
381 Seguindo87 Seguidores
Exciting presentation at #ET24
Thank you @NaglaAKarimMD and the speakers
Dr. Nagla Abdel Karim@NaglaAKarimMD
@DCCancerDoc chaired the session for Areas of Unmet Needs to be considered for future drug development in Oncology #ET24. Stay Tuned for next years’ exciting topics! @InovaCME @InovaSchar @InovaHealth
English
Dalia M. retweetou
@DCCancerDoc chaired the session for Areas of Unmet Needs to be considered for future drug development in Oncology #ET24. Stay Tuned for next years’ exciting topics! @InovaCME @InovaSchar @InovaHealth
English
Dalia M. retweetou
@MPishvaian How to improve accrual/Discover the clues to success of Phase I Programs #ET24 @InovaSchar @InovaHealth @InovaCME
English
Dalia M. retweetou
@AnwaarSaeed3 presents Novel Agents Exploration in MRD Positive Colorectal Cancer Post Definitive Surgery and Chemotherapy. Excellent point of utilizing potentially effective novel agents in the adjuvant setting #ET24
English
Finally met papa Hem in person
Symposium for Evolving Therapies and Drug Development in Oncology
INOVA
@AaronGoodman33
@NaglaAKarimMD
English
@SamahNd @Cancer_talks @GWCancer
Excellent talk on AML at 2024 Hematology Update Symposium by
Dr. Nassereddine
English
Dalia M. retweetou
@Dr_AmerZeidan Do your best work to prolong life and alleviate suffering, advocate tirelessly for your patients, have a life outside of medicine - and always remember that it is the patient's story that you were privileged to witness and play a role in, not your story.
English
A coffee and baklava is all what you need for a good day..
English
Dalia M. retweetou
#سورة_الكهف
#يوم_الجمعة
اسقوا غِراس جُمعتكم بـ سورة الكهف
فإنها نورٌ بين الجُمعتين .. 🤍
العربية
Small Cell Lung Cancer SCLC SOC discussed by Dr. @StephenVLiu at #DCLung22 with highlights including promising agents. Scratching the surface still with biomarkers
English
@Cancer_talks @StephenVLiu #DCLung22 excellent presentation Dr. Haroun at the D.C. Lung Cancer Conference 2022
Stephen V Liu, MD@StephenVLiu
Dr. Faysal Haroun @Cancer_talks discusses the different 1L chemo-free IO options in NSCLC. Despite crossover, clear OS benefit makes 1L IO the clear SOC but different delivery options. Dual checkpoint blockade with impressive long term OS but in need of biomarkers. #DCLung22
English
Stephen V Liu, MD@StephenVLiu
Antibody drug conjugates increasingly relevant for NSCLC as discussed by Dr. @benlevylungdoc at #DCLung22 with highlights including trastuzumab deruxtecan (T-DXd) in #HER2 mutant NSCLC (dose is 5.4 mg/kg) and patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC. #LCSM
QME
Stephen V Liu, MD@StephenVLiu
Update on #ROS1 NSCLC by Dr. @JessicaJLinMD at #DCLung22 including latest data on repotrectinib from #ENA2022. Promising activity with novel agents including against ROS1 G2032R especially NVL-520 with compelling (early) efficacy and safety data, first presented a few days ago!
QHT
Dalia M. retweetou
Learning about the potential benefit of proton beam radiation from Dr. @NitikaPaudel at #DCLung22 - single gantry model at @LombardiCancer shown. Newer technology showing less exposure vs passive scatter. Awaiting results from ongoing #RTOG study.
English